BR112018003252A2 - polipeptídeos mrka, anticorpos, e usos dos mesmos - Google Patents

polipeptídeos mrka, anticorpos, e usos dos mesmos

Info

Publication number
BR112018003252A2
BR112018003252A2 BR112018003252A BR112018003252A BR112018003252A2 BR 112018003252 A2 BR112018003252 A2 BR 112018003252A2 BR 112018003252 A BR112018003252 A BR 112018003252A BR 112018003252 A BR112018003252 A BR 112018003252A BR 112018003252 A2 BR112018003252 A2 BR 112018003252A2
Authority
BR
Brazil
Prior art keywords
mrka
klebsiella
antibodies
fragments
subject
Prior art date
Application number
BR112018003252A
Other languages
English (en)
Portuguese (pt)
Inventor
Kendall Stover Charles
Chang Chew-Shun
Lin Hung-Yu
Heidbrink Thompson Jenny
Pennini Meghan
S Chowdhury Partha
Wang Qun
Rajan Saravanan
Dall'acqua William
Xiao Xiaodong
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BR112018003252A2 publication Critical patent/BR112018003252A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112018003252A 2015-08-24 2016-08-23 polipeptídeos mrka, anticorpos, e usos dos mesmos BR112018003252A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US201562238828P 2015-10-08 2015-10-08
PCT/US2016/048221 WO2017035154A1 (en) 2015-08-24 2016-08-23 Mrka polypeptides, antibodies, and uses thereof

Publications (1)

Publication Number Publication Date
BR112018003252A2 true BR112018003252A2 (pt) 2018-09-25

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003252A BR112018003252A2 (pt) 2015-08-24 2016-08-23 polipeptídeos mrka, anticorpos, e usos dos mesmos

Country Status (16)

Country Link
US (2) US20170073397A1 (enExample)
EP (1) EP3341004A4 (enExample)
JP (1) JP2018527924A (enExample)
KR (1) KR20180042300A (enExample)
CN (1) CN107921086A (enExample)
AU (1) AU2016313653A1 (enExample)
BR (1) BR112018003252A2 (enExample)
CA (1) CA2995387A1 (enExample)
CL (1) CL2018000357A1 (enExample)
CO (1) CO2018001985A2 (enExample)
HK (1) HK1252350A1 (enExample)
IL (1) IL257434A (enExample)
MX (1) MX2018001964A (enExample)
RU (1) RU2018107056A (enExample)
TW (1) TW201718626A (enExample)
WO (1) WO2017035154A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900027XA (en) * 2016-08-05 2019-02-27 Medimmune Llc Anti-o2 antibodies and uses thereof
WO2018075375A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
JP2020525540A (ja) 2017-06-23 2020-08-27 ノソコミアル ヴァクスィーン コーポレイション 免疫原性組成物
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725B (zh) * 2023-07-06 2025-11-04 深圳康泰生物制品股份有限公司 肺炎克雷伯菌的FimA的抗原表位肽及其应用
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2005034733A2 (en) * 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2152731A2 (en) * 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2012058334A1 (en) * 2010-10-26 2012-05-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Morphology & protein specific reagents as diagnostics for neurodegenerative diseases
SMT202000542T1 (it) * 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas

Also Published As

Publication number Publication date
HK1252350A1 (zh) 2019-05-24
CL2018000357A1 (es) 2018-07-20
JP2018527924A (ja) 2018-09-27
TW201718626A (zh) 2017-06-01
US20170073397A1 (en) 2017-03-16
AU2016313653A1 (en) 2018-04-12
CO2018001985A2 (es) 2018-11-22
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
CN107921086A (zh) 2018-04-17
MX2018001964A (es) 2018-06-19
US20190062411A1 (en) 2019-02-28
EP3341004A1 (en) 2018-07-04
EP3341004A4 (en) 2019-05-15
WO2017035154A1 (en) 2017-03-02
KR20180042300A (ko) 2018-04-25
CA2995387A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112018003252A2 (pt) polipeptídeos mrka, anticorpos, e usos dos mesmos
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
BR112017027549A2 (pt) anticorpo para cd40
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
BR112016004324A2 (pt) anticorpos
MX2022012089A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
BR112019002039A2 (pt) anticorpos anti-o2 e uso dos mesmos
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
BR112015014621A2 (pt) Anticorpos anti-h7cr
BR112018068678A2 (pt) anticorpos anti-mica
BR112017025533A2 (pt) método para tratar câncer em um paciente humano

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]